proposal penelitian - USU Institutional Repository

DAFTAR PUSTAKA
1. Keane WF, Lyle PA. Kidney disease and cardiovascular disease:
Implication of dyslipidemia. Elsevier Saunders.Cardiol clin 2005 ; 23:
363-72.
2. Ozsoy RC, Leuven SI, Kastelein JJP et al. The dyslipidemia of chronic
renal disease: effects of statin therapy. Departments of nephrology and
vascular medicine, the academic medical centre, University of
Amsterdam,The Netherlands. Current opinion in Lipidology 2006 ; 17(6) :
659-66
3. Tsimihodimos V, Dounousi E, Siamopoulos KC . Dyslipidemia in
chronic kidney disease: An Approach to pathogenesis and treatment. Am J
Nephrol 2008; 28: 958-73.
4. De Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to
hemodynamic determinants of left ventricular hypertrophy. Hypertension.
2001; 38: 13-8
5. Scillaci G, Vaudo G, Reboldi G, et al. High density lipoprotein cholesterol
and left ventrivular hypertrophy in essential hypertension. J Hypertens
2001; 19: 2265-70
6. Kanbay M, Turgut F, Covic A, et al. Statin treatment for dyslipidemia in
chronic kidney disease and renal transplantation: a review of the evidence.
J Nephrol.2009 ; 22: 598-609.
7. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney
disease. J Gen Intern Med.2004 ;19:1045-52.
8. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc
Nephrol.2003; 14 : S315-20
9. Vaziri ND 2006. Dyslipidemia of chronic renal failure: the nature,
mechanisms, and potential consequences. Am J Physiol Renal Physiol.
2006 ; 290 : F 262-72.
10. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of
death,cardiovascular events, and hospitalization. N Engl j med.2004; 351:
1296-305.
11. Wali RK, Henrich WL. Chronic kidney disease:A risk factor for
cardiovascular disease. Elsevier Saunders, Cardiol clinic. 2005; 23 : 34362.
12. Schiffrin EL, Lipman ML,Mann JFE 2007. Chronic kidney disease: Effect
on the cardiovascular system. Circulation. 2007; 116 : 85-97.
13. Gosmanova EO, Le NA. Cardiovascular complication in CKD patients:
Role of oxidative stress. Cardiology research and practice,2011: 1-8.
14. Nitta K. Possible link between metabolic syndrome and chronic kidney
disease in the development of cardiovascular disease. Cardiology research
and practice 2011: 1-7.
15. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and
cardiovascular disease in a general Japanese population: The Hisayama
Study. Kidney Int,2005; 68 : 228-36.
Universitas Sumatera Utara
16. Samak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk
factor for development of cardiovascular disease: A Statement from the
American Heart Association Councils on Kidney in cardiovascular
disease, High blood pressure research clinical cardiology & epidemiology
& prevention. Circulation.2003; 108 : 2154-69.
17. Ikee R, hamasaki Y, Oka M, et al. High density lipoprotein cholesterol and
left ventricular mass index in peritoneal dialysis. Perit Dial Int.2008; 28 :
611-16.
18. Dhinra R, Gaziano JM, Djousse L. Chronic kidney disease and the risk
of heart failure in men. Circ Heart Fail.2011; 4 : 138-44.
19. Bauml MA, Underwood DA . Left ventricular hypertrophy: An overlooked
cardiovascular risk factor. Cleveland clinic journal of medicine. 2010; 77 :
1-6.
20. Zoccali C. Left ventricular mass index as an outcome measure in clinical
trials in dialysis patients: A word of caution. Am J Nephrol. 2011; 33 :
370-72.
21. Dahlan S. Menghitung besar sampel In: Besar sampel dalam penelitian
kedokteran dan kesehatan. Arkans 2005 : 64-70.
22. Madiyono B, Moeslichan S, Sastroasmoro S, et al. Perkiraan besar
sampel. In: Sastroasmoro S, Ismael S, eds. Dasar-dasar Metodologi
penelitian klinis. 3rd ed. Sagung Seto 2008 : 302-12.
23. PERKENI 2012, Kosensus pengelolaan dislipidemia di Indonesia.
24. Foppa M, Duncan BB, Rohde LEP. Echocardiography based left
ventricular mass estimation.How should we define hypertrophy? Bio Med
Central.2005; 3 :17
25. Colossimo AP, Costa FDA, Riera ARP, et al. Electrocardiogram
sensitivity in left ventricular hypertrophy according to gender and cardiac
mass. Arq Bras cardiol.2011 : 0-0.
26. Anan F, Yonemochi H, Masaki T, et al. High density lipoprotein
cholesterol and insulin resistence are independent and additive markers of
left ventricular hypertrophy in essential hypertension. Hypertens Res 2007;
30: 125-31.
27. Sundstrom J, Lind L, Vessby B, et al. Dyslipidemia and an unfavorable
fatty acid profile predict left ventricular hypertrophy 20 years later.
Circulation 2001; 103: 836-41.
28. Kjeldsen SE, Strand A, Julius S et al. Mechanism of Angiotensin II Type 1
Receptor Blocker Action in the Regression of Left Ventricular
Hypertrophy. J Clin Hypertens.2006; 8: 487-92
29. Gunawan RI, Kosasih A, Lilyasari O, et al. Correlation Between
Circulating Leptin Level With Left Ventricle Mass in Normotensive men.
J Kardiol Ind 2007; 28: 343-53
30. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE
inhibitors induces a regression of left ventricular hypertrophy of dialyzed
uremic patients independently from hypotensive effects.AJKD 1997;60
31. Konstam MA. Role of angiotensin converting enzyme inhibitors in
preventing left ventricular remodelling following myocardial infarction.
European Heart Journal 1995; 16: 42-8
Universitas Sumatera Utara
32. Mathew J, Sleight P, Lonn E, et al. Reduction of Cardiovascular Risk by
Regression of Electrocardiographic Markers of Left Ventricular
Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor
Ramipril.Circulation 2001; 104: 1615-21
Universitas Sumatera Utara

Download Report